RGBP (Regen BioPharma) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regen BioPharma 3-Year EBITDA Growth Rate?

Regen BioPharma RGBP +50.00% 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,137 Biotechnology companies, Regen BioPharma ranks worse than 87950.66% on this metric.

Regen BioPharma's EBITDA per Share for the three months ended in Mar. 2026 was $0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regen BioPharma was 74.40% per year. The lowest was -58.00% per year. And the median was 5.80% per year.

Regen BioPharma  (OTCPK:RGBP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Regen BioPharma 3-Year EBITDA Growth Rate Related Terms

RGBP vs SIGY, ENDV, CNBX: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Regen BioPharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's 3-Year EBITDA Growth Rate falls into.


Regen BioPharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Regen BioPharma (RGBP) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 1137 companies in the Biotechnology industry.
Is Regen BioPharma's 3-Year EBITDA Growth Rate too high?
Regen BioPharma's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Regen BioPharma ranks #999999 out of 1137 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's 3-Year EBITDA Growth Rate compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Regen BioPharma in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 15.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 15.00, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regen BioPharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 15.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.